Claire Mazumdar

CIK: 0002034671

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)17 (43.6%)

Position reduction

Option Exercises (M)19 (48.7%)

Derivative conversions

Awards (A)3 (7.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BCAX

Bicara Therapeutics Inc.

DirectorOfficer

RLAY

Relay Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (39 total)

BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Sale(S)
Direct
10K shares at avg. $27.98$280K
BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Exercise(M)
Direct
10K shares at avg. $3.79$38K
BCAX
Bicara Therapeutics Inc.
Jul 10, 2026
Exercise(M)
Direct
10K shares at avg. $3.79$38K
BCAX
Bicara Therapeutics Inc.
Jul 10, 2026
Sale(S)
Direct
28 shares at avg. $29.68$831.04
BCAX
Bicara Therapeutics Inc.
Jul 10, 2026
Sale(S)
Direct
10K shares at avg. $28.42$283K
RLAY
Relay Therapeutics, Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
32.9K shares-
BCAX
Bicara Therapeutics Inc.
May 18, 2026
Sale(S)
Direct
12K shares at avg. $19.96$240K
BCAX
Bicara Therapeutics Inc.
May 18, 2026
Sale(S)
Direct
3K shares at avg. $20.35$61K
BCAX
Bicara Therapeutics Inc.
May 18, 2026
Exercise(M)
Direct
15K shares at avg. $3.79$57K
BCAX
Bicara Therapeutics Inc.
Apr 20, 2026
Sale(S)
Direct
15K shares at avg. $23.61$354K
BCAX
Bicara Therapeutics Inc.
Apr 20, 2026
Exercise(M)
Direct
15K shares at avg. $3.79$57K
BCAX
Bicara Therapeutics Inc.
Apr 16, 2026
Exercise(M)
Direct
7.5K shares at avg. $3.79$28K
BCAX
Bicara Therapeutics Inc.
Apr 16, 2026
Exercise(M)
Direct
7.1K shares at avg. $5.45$39K
BCAX
Bicara Therapeutics Inc.
Apr 16, 2026
Exercise(M)
Direct
8.2K shares at avg. $4.44$36K
BCAX
Bicara Therapeutics Inc.
Mar 20, 2026
Sale(S)
Direct
1.6K shares at avg. $18.95$30K
BCAX
Bicara Therapeutics Inc.
Mar 20, 2026
Exercise(M)
Direct
1.6K shares at avg. $3.79$6K
BCAX
Bicara Therapeutics Inc.
Mar 19, 2026
Exercise(M)
Direct
6.9K shares at avg. $3.79$26K
BCAX
Bicara Therapeutics Inc.
Mar 19, 2026
Sale(S)
Direct
6.9K shares at avg. $18.78$130K
BCAX
Bicara Therapeutics Inc.
Mar 18, 2026
Sale(S)
Direct
6.5K shares at avg. $18.84$122K
BCAX
Bicara Therapeutics Inc.
Mar 18, 2026
Exercise(M)
Direct
6.5K shares at avg. $3.79$25K
BCAX
Bicara Therapeutics Inc.
Mar 9, 2026
Sale(S)
Direct
36.8K shares at avg. $19.17$705K
BCAX
Bicara Therapeutics Inc.
Mar 9, 2026
Exercise(M)
Direct
36.8K shares at avg. $3.79$139K
BCAX
Bicara Therapeutics Inc.
Mar 6, 2026
Sale(S)
Direct
3.8K shares at avg. $18.75$72K
BCAX
Bicara Therapeutics Inc.
Mar 6, 2026
Exercise(M)
Direct
3.8K shares at avg. $3.79$14K
BCAX
Bicara Therapeutics Inc.
Mar 5, 2026
Exercise(M)
Direct
1.8K shares at avg. $3.79$7K

		Type	Shares	Price		Ownership
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	10,000	$27.98	$279,750	Direct
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	10,000	$3.79	$37,898	Direct
Jul 10, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	10,000	$3.79	$37,898	Direct
Jul 10, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	28	$29.68	$831	Direct
Jul 10, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	9,972	$28.42	$283,367	Direct
Jun 9, 2026	RLAY Relay Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	32,947	-	-	Direct
May 18, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	12,022	$19.96	$239,982	Direct
May 18, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	2,978	$20.35	$60,597	Direct
May 18, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	15,000	$3.79	$56,847	Direct
Apr 20, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	15,000	$23.61	$354,146	Direct
Apr 20, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	15,000	$3.79	$56,847	Direct
Apr 16, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	7,454	$3.79	$28,249	Direct
Apr 16, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	7,080	$5.45	$38,612	Direct
Apr 16, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	8,226	$4.44	$36,498	Direct
Mar 20, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	1,596	$18.95	$30,246	Direct
Mar 20, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	1,596	$3.79	$6,049	Direct
Mar 19, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	6,905	$3.79	$26,169	Direct
Mar 19, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	6,905	$18.78	$129,705	Direct
Mar 18, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	6,499	$18.84	$122,415	Direct
Mar 18, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	6,499	$3.79	$24,630	Direct
Mar 9, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	36,766	$19.17	$704,657	Direct
Mar 9, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	36,766	$3.79	$139,336	Direct
Mar 6, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	3,817	$18.75	$71,572	Direct
Mar 6, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	3,817	$3.79	$14,466	Direct
Mar 5, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	1,786	$3.79	$6,769	Direct

1-25 of 39 transactions

About Mazumdar Claire

Mazumdar Claire (SEC CIK 0002034671) files insider reports with the SEC as Chief Executive Officer of Bicara Therapeutics Inc. (BCAX) and Director of Relay Therapeutics, Inc. (RLAY).

Signal8 holds 16 ownership filings by Mazumdar Claire (2 Form 3, 14 Form 4), filed between Sep 12, 2024 and Aug 12, 2026. Those filings report 39 transactions, from Jun 9, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mazumdar Claire's filings is in BOSTON, MA.

Recent filings by Mazumdar Claire

Aug 10, 2026: Open-market sale of BCAX shares (Form 4, code S).
Aug 10, 2026: Option exercise of BCAX shares (Form 4, code M).
Jul 10, 2026: Option exercise of BCAX shares (Form 4, code M).
Jul 10, 2026: Open-market sales of BCAX shares (2 lines, Form 4, code S).
Jun 9, 2026: Grant or award of RLAY derivative securities (Form 4, code A).

Other insiders filing for Bicara Therapeutics Inc. (BCAX)

Cohlhepp Ryan, President, COO & Interim CEO
Larson Jennifer, Chief Financial Officer
Hyep Ivan, Chief Financial Officer
Bender Jeremy, Director
Oliger Christy J., Director
RA CAPITAL MANAGEMENT, L.P., Director

How to read Form 4 transaction codes